Pivotal Therapeutics Exhibiting at The American College of Cardiology 61st Annual Scientific Session & Expo
(firmenpresse) - WOODBRIDGE, ONTARIO -- (Marketwire) -- 02/29/12 -- Pivotal Therapeutics Inc. (CNSX: PVO), a specialty pharmaceutical company with a focus on the treatment of cardiovascular disease, is pleased to announce that the company will be exhibiting at the 61st Annual Scientific Session & Expo of The American College of Cardiology ("ACC") in Chicago, March 24-27, 2012, Booth #24020.
The annual meeting of the ACC is unsurpassed among clinical cardiology meetings and is one of the most highly attended and respected events in cardiovascular medicine. It is a forum for the latest and most innovative findings in cardiovascular science, as well as the most clinically relevant practical applications.
"As part of our continuing efforts to create awareness of VASCAZEN™ we are pleased to have the opportunity to be exhibiting at the annual conference of the ACC", said Eugene Bortoluzzi, CEO. "This conference will afford us the opportunity to interact with more than 13,000 cardiovascular professionals who are expected to attend the conference."
About Pivotal Therapeutics Inc.
With offices in Toronto, Canada and Boca Raton, Florida, Pivotal Therapeutics is a publicly traded (CNSX: PVO) specialty pharmaceutical company with a focus on the treatment of cardiovascular disease and overall health. Pivotal Therapeutics' lead product VASCAZEN™ is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) to levels associated with reduced risk of cardiovascular complications.
OMAZEN™ is a greater than 90% pure, proprietary EPA:DHA fatty acid formulation commercialized for sale and distribution in Canada for the maintenance of good health through elevating Omega-3 fatty acid levels. The unique formulation and dosage will be available to patients and consumers who realize the health benefits of Omega-3 supplementation with a quality product.
VASCAZEN™ is a greater than 90% pure, proprietary EPA:DHA fatty acid formulation, protected by a series of both issued and pending US and foreign patents and commercialized by prescription only. This unique formulation will provide the cornerstone upon which a family of cutting edge combination products, with efficacy across a broad spectrum of cardiac care, will be commercialized.
Disclosure Notice
The information contained in this document is as of February 29, 2012. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSNX listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments.
Contacts:
Investor Relations Contact:
The Shoreham Group, LLC
Timothy J. Ryan, Managing Director
212-242-7777
Company Contact:
Pivotal Therapeutics Inc.
Rachelle MacSweeney, President
905-856-9797
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.02.2012 - 14:18 Uhr
Sprache: Deutsch
News-ID 1088450
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
WOODBRIDGE, ONTARIO
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 193 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pivotal Therapeutics Exhibiting at The American College of Cardiology 61st Annual Scientific Session & Expo
"
steht unter der journalistisch-redaktionellen Verantwortung von
Pivotal Therapeutics Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
